Martin Hossann

Martin Hossann is a German scientist and entrepreneur who is best known for their work in the field of thermosensitive liposomes. Martin is the co-founder and principal scientist at Thermosome, a company that specializes in the development of these liposomes for use in target-directed therapy of solid tumours.

Hossann began their career as a postdoc at the University Hospital of Munich, where they worked on the development of novel thermosensitive liposomes for target-directed therapy of solid tumours in combination with hyperthermia. Martin then moved to Max Planck Innovation GmbH, where they served as a scientific project manager before returning to the University Hospital of Munich in 2010 to head up a laboratory.

In 2015, Hossann left the University Hospital of Munich to co-found Thermosome, where they continue to work on the development of thermosensitive liposomes for use in cancer treatment.

Martin Hossann studied chemistry at the University of Kaiserslautern, Germany, earning a Dr. rer. nat. (PhD) and a Diplom-Chemiker (Masters). Martin is certified by the Gesellschaft Deutscher Chemiker (GDCh; German Chemical Society) as a Geprüfter Qualitätsexperte GxP (GDCh Certified Quality Expert) and as a Geprüfter Projektmanager Wirtschaftschemie (GDCh Certified Project Manager for Industrial Chemistry).

Martin Hossann reports to Pascal Schweizer, Co-Founder & CEO & CFO. Martin Hossann works with Lars Lindner - Co-Founder & Clinical Advisor, Klaus Fischer - CDO, and Wolfgang Schwandner - Managing Director.